PARSIPPANY, N.J., April 24, 2023 /PRNewswire/ -- Ascensia Diabetes
Care, a global diabetes care company, maker of the
CONTOUR® Blood Glucose Monitoring (BGM) system
portfolio and exclusive distributor of
Eversense® Continuous Glucose Monitoring (CGM)
Systems, marks the one-year anniversary of launching
Eversense® E3 in the U.S. with a commercial update
and outlook on future innovation, as discussed in the recent
Eversense CGM Virtual Analyst and Investor Event.
![Ascensia Diabetes Care Logo Ascensia Diabetes Care Logo](https://mma.prnewswire.com/media/749389/Ascensia_Diabetes_Care_Logo.jpg)
"The last year has really seen our partnership with Senseonics go
from strength to strength," said Rob
Schumm, President and CEO of Ascensia Diabetes Care. "At
Ascensia we've been focused on driving the uptake of this highly
differentiated product, and we are encouraged to see more patients
accessing its benefits. Meanwhile, Senseonics has been focused on
delivering innovation based on the feedback that we both hear from
patients. Together, we have an ambitious vision for what the
diabetes management of tomorrow looks like, and we are increasingly
excited about what the future holds."
In April 2022, Ascensia launched
the Eversense® E3 CGM System for patients in the
U.S., shortly after it was approved by the U.S. Food and Drug
Administration (FDA). Developed by Senseonics, the system includes
the longest lasting CGM sensor available, with up to six-months of
wear, compared to just one or two weeks with most CGM systems.
Alongside improved longevity, this next-generation system also
offers people with diabetes unique and competitive features such as
a fully implantable sensor, a removable smart transmitter*,
discreet on-body vibe alerts, exceptional accuracy1 and
an intuitive smartphone app. Key highlights from the past year
include:
U.S. Commercial Highlights
- Significant coverage success with over 250 million covered
lives, including favorable Medicare reimbursement and coverage from
nearly all major national insurers
- Number of Eversense users significantly expanded since the
launch of Eversense E3, providing a foundation for the strong
growth that we expect in the US this year
- Continuation of PASS (Payment Assistance and Simple Savings)
Program to reduce out-of-pocket expenses for Eversense users
with insurance coverage
- Growing number of certified inserters, supplemented by a
network of certified mobile and at-home inserters through the Nurse
Practitioner Group partnership
- Increasing opportunity for people living with type 2 diabetes,
with type 2 diabetes patients accounting for half of those using
the system
- Majority of our new users are moving from their current
CGM to Eversense
- Ongoing expansion of our dedicated CGM salesforce to help
drive Eversense awareness and adoption
Innovation Outlook
- ENHANCE pivotal clinical trial for the 365-day sensor is
underway, with plans to submit data to the FDA for potential
approval, targeted for mid-2024
- Pediatric cohort has started enrolling, evaluating the use of
Eversense in youth
- Executing plans with a goal to achieve iCGM
(integrated CGM) clearance and integration
for Eversense with automated insulin delivery (AID)
systems
- The Gemini development program, investigating products with
both real-time CGM monitoring and on-demand intermittent
scanning to provide increased flexibility for patients
- Work underway towards the Eversense Freedom system, which
captures all the current features and benefits of Eversense
but with no on-body components
Last year's launch was an important landmark in the global
partnership between Ascensia and Senseonics, which has supported
both patient access to Eversense and the development of future
products, by allowing both companies to focus on their core
strengths. Senseonics remains responsible for research,
development, innovation, and manufacturing while Ascensia is able
to leverage its market-leading position in BGM to exclusively lead
worldwide marketing and commercialization.
Eversense CGM Systems and the Eversense CGM App are available
across the US and select countries in Europe. Please visit
www.ascensia.com/eversense for more information. To learn more,
please refer to the recent Eversense CGM Virtual Analyst and
Investor Event hosted by Ascensia, Senseonics Holdings (NYSE: SENS)
and PHC Holdings Corporation (TSE: 6523).
1 Garg, S. K. et al. (2021). Evaluation of
Accuracy and Safety of the NextGeneration Up to 180-Day Long-Term
Implantable Eversense Continuous Glucose Monitoring System: The
PROMISE Study. Diabetes Technology & Therapeutics, 24(2), 1-9.
DOI: 10.1089/dia.2021.0182
*There is no glucose data generated when the transmitter is
removed.
Logo -
https://mma.prnewswire.com/media/749389/Ascensia_Diabetes_Care_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/ascensia-diabetes-care-marks-one-year-anniversary-of-us-eversense-e3-cgm-launch-with-commercial-update-and-innovation-outlook-301804412.html
SOURCE Ascensia Diabetes Care